Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy
University of Edinburgh
100 participants
Aug 8, 2025
INTERVENTIONAL
Conditions
Summary
The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms. This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.
Eligibility
Inclusion Criteria3
- Males and females \>18 years of age
- Clinical presentation of takotsubo cardiomyopathy
- Have capacity to give formal consent
Exclusion Criteria11
- Unable to tolerate or contraindication to magnetic resonance imaging
- Renal failure (estimated glomerular filtration rate \<30 mL/min/1.73 m2) - this would be assessed by performing a blood test
- Prior history of cardiomyopathy
- Current pregnancy
- Weight greater than 250kg
- Severe asthma for study 1 (given Bisoprolol is contraindicated in this condition)
- Type 1 diabetes mellitus for study 2 (given Dapaglifozin is contraindicated in this population)
- Significant hypotension (given the medications prescribed as part of the study can also cause hypotension as a side effect)
- Significant bradycardia for study 1 (given Bisoprolol can exacerbate any pre-existing significant bradycardia)
- Prescribed Digoxin (this medication interacts with the Manganese)
- Unable to give formal consent
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Participants will be randomised to receive Bisoprolol medication.
Participants will be randomised to receive Valsartan medication.
Participants will be randomised to receive Sacubitril/Valsartan medication first.
Participants will be randomised to receive Dapaglifozin medication first.
Participants will be randomised to receive no study medication.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07491718